First Patient Dosed in Clairvoyant’s Phase 2 Clinical Trial Exploring Psilocybin as a Treatment for Alcohol Use Disorder

November 3, 2022 5:00 AM

VANCOUVER, BC / ACCESSWIRE / November 3, 2022 / Clairvoyant Therapeutics ("Clairvoyant"), a clinical stage biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce the first patient has been dosed in the company's Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD).Clairvoyant's randomized, controlled, clinical trial, CLA-PSY-201,...

Read more

Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

November 3, 2022 3:20 AM

A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) populationA reduction in the risk of death at day 90 of 43% in the ITT population and 70% in the PP populationThe start of regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations in 2023PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / November 3,...

Read more

Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 2, 2022 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDTElarekibep (PRS-060/AZD1402) phase 2a study for asthma enrollment continuesFirst subject dosed in PRS-220 phase 1 study for idiopathic pulmonary fibrosis (IPF)PRS-344/S095012 phase 1 study for solid tumors in collaboration with Servier continuesIND accepted for SGN-BB228 (also known as PRS-346) phase 1 immuno-oncology study; preclinical data to be presented...

Read more

Apollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter 2022

November 1, 2022 4:01 PM

Grew global revenue 20% GAAP, 24% in constant currencyReceived FDA authorization for Apollo ESGTM and Apollo REVISETM systems for treating patients with obesityAUSTIN, TX / ACCESSWIRE / November 1, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2022 and recent...

Read more

One Step Ahead of ICER Assessment: Innopiphany's Sentinnel AI Revolutionizes Value Assessment Readiness

November 1, 2022 10:30 AM

IRVINE, CA / ACCESSWIRE / November 1, 2022 / Innopiphany, LLC is thrilled to announce the release of its proprietary* predictive software, Sentinnel. This groundbreaking machine-learning application draws from our unique database to forecast a product's likelihood of a future ICER** assessment. ICER is an independent drug pricing watchdog that publishes reports analyzing the value and estimating a price for new treatments.Drawing from data on...

Read more

Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study

November 1, 2022 9:25 AM

Lexaria's DehydraTECH-nicotine pouch performance to be compared to existing leading brands ON! and ZynKELOWNA, BC / ACCESSWIRE / November 1, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that independent review board ("IRB") approval has now been received for human clinical nicotine study NIC-H22-1, and that human dosing will begin...

Read more

Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

November 1, 2022 9:15 AM

BOSTON, MA / ACCESSWIRE / November 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the first subject has been dosed in the phase 1 study of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor (CTGF) for...

Read more

Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394

November 1, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company who develops monoclonal antibodies targeting treatment of various cancers, announced today that the United States Patent and Trademark Office (the "USPTO") will issue patent No. 11,492,394 on November 8, 2022 for claims related to the Company's lead candidate Pritumumab.The...

Read more

BrainChip Appoints Duy-Loan Le to its Board of Directors

October 31, 2022 8:00 PM

LAGUNA HILLS, CA / ACCESSWIRE / October 31, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, announces the appointment of Duy-Loan Le to its Board of Directors, as a non-executive director.Mrs. Le has a remarkable professional history, both technologically and in executive management, having retired from Texas Instruments as a Senior Fellow after 35...

Read more

UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform

October 31, 2022 8:40 AM

- Research grants provided by the National Cancer Institute will support continued development and study of cowpea mosaic virus (CPMV) as an immuno-oncology candidate -- One grant will focus on optimization of methods of large-scale production and to perform studies designed to satisfy regulatory requirements for human clinical development - the other grant will focus on development of CPMV as a platform technology -NOVATO, CA / ACCESSWIRE /...

Read more

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product

October 31, 2022 8:05 AM

~ Announces Timing of Corporate Update Call ~SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced positive topline results from a human abuse potential (HAP) study for PF614. PF614 is a new class of analgesia,...

Read more

Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Platform

October 31, 2022 8:00 AM

- Research grants provided by the National Cancer Institute will support continued development and study of cowpea mosaic virus (CPMV) as an immuno-oncology candidate -- One grant will focus on optimization of methods of large-scale production and to perform studies designed to satisfy regulatory requirements for human clinical development - the other grant will focus on development of CPMV as a platform technology -NOVATO, CA / ACCESSWIRE /...

Read more

Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study

October 28, 2022 9:40 AM

~ Critical Study to Support Abuse Deterrent Labeling ~SAN DIEGO, CA / ACCESSWIRE / October 28, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced the first subjects dosed in the PF614-104 study, ‘A Randomized, Double-blind, Placebo and...

Read more

EastWest Bioscience Announces Shares for Debt Settlements

October 27, 2022 6:00 PM

VANCOUVER, BC / ACCESSWIRE / October 27, 2022 / EastWest Bioscience Inc. (the "Company" or "EastWest") (TSXV:EAST) announces the proposed issuance of 1,436,020 common shares at a price of CDN $0.05 per common share to certain non-arm's length service providers for consulting services carried out for the Company (collectively, the "Transactions"). The Transactions were in the normal course of business and the consideration provided was agreed to...

Read more

enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update

October 27, 2022 4:05 PM

- Ended the quarter with $42.7 million in cash and investments- Burn rate of $4.5 million for the quarter- Runway extends through the end of 2024 including release of SAVVE topline pivotal trial data and initiation of TAVVE first in human studyIRVINE, CA / ACCESSWIRE / October 27, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...

Read more

BioInvent International AB: Interim report January-September 2022

October 27, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / October 27, 2022 / BioInvent International (STO:BINV)"BioInvent further strengthened its financial position in the third quarter through a directed share issue. With this solid foundation, we have continued our strong clinical progress and look forward to a number of significant drug development milestones." - Martin Welschof, CEO of BioInvent.EVENTS IN THE THIRD QUARTER• (R) BioInvent successfully carried out a...

Read more

Media Alert: BrainChip Showcases Its Essential AI at IoT World

October 26, 2022 5:30 PM

LAGUNA HILLS, CA / ACCESSWIRE / October 26, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, today announced that Rob Telson, Vice President of Ecosystem and Partnerships, will present "Essential AI: Efficient, Effective, Everywhere" at IoT World & The AI Summit Austin at the Austin Convention Center in Austin, Texas, November 2 at 12:30 p.m. CDT....

Read more

Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022

October 26, 2022 8:00 AM

BOSTON, MA / ACCESSWIRE / October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2022 investor call on Wednesday, November 2, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate...

Read more

NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1

October 26, 2022 7:00 AM

NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1FDA Expands the Scope of the Company's SubmissionAccelerates Path Toward Immunotherapy for Glioblastoma (Brain Cancer)CLEVELAND, OH / ACCESSWIRE / October 26, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the approval of its application with the U.S. Food and Drug Administration...

Read more

New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy

October 25, 2022 9:00 AM

Expanded STENDRA Labeling Now Includes Data on a Significant Population of Men Not Previously Included Following Submission of Additional Clinical Trial DataNEW YORK, NY / ACCESSWIRE / October 25, 2022 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announces the expansion of the FDA labeling for its oral erectile dysfunction (ED) drug, STENDRA® (avanafil), marketed by its subsidiary,...

Read more